[1] NORGAARD M,JENSEN AO,ENGEBJERG MC,et al.Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia:a Danish population-based cohort study[J].Blood,2011,117(13):3514.
[2] PROVAN D,STASI R,NEWLAND Ac,et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood,2010,115(2):168.
[3] 中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):975.
[4] 张之南,郝玉书,赵永强,等,血液病学[M].2版.北京：人民卫生出版社,2012:1273.
[5] WANG T,WANG Z,YANG R.Thrombopoietic growth factors in the treatment of immune thrombocytopenic purura[J].Crit Rev Oncol Hematol,2011,77(3):172.
[6] KUTER DJ.New drugs for familiar therapeutic targets:thrombopoietin receptor agonists and immune thrombocytopenic purpura[J].Eur J Haematol Suppl,2008,80(69):9.
[7] 郑杰,马静瑶,苏雁,等.重组人血小板生成素治疗儿童重症免疫性血小板减少症25例临床观察[J].中国实验血液学杂志,2014,22(2):393.
[8] 殷献录,李静,姚伟,等.小剂量利妥昔单抗治疗难治性免疫性血小板减少症临床观察[J].淮海医药,2015,33(1):10.
[9] 刘晓帆,黄月婷,刘葳,等.重组人血小板生成素治疗92例成人重型原发性免疫性血小板减少症的临床观察[J].中华血液学杂志,2015,36(4):312.
[10] 苗文春,陈岳华,蒋志相,等.重组人血小板生成素治疗免疫性血小板减少症的临床观察[J].浙江临床医学,2014,16(1):97.
[11] 邹江,刘泽法.重组人血小板生成素治疗急性白血病化疗所致血小板减少的临床观察[J].医学信息,2013,26(10):269.
[12] 杜以萍,张充力,毕珍宁.糖皮质激素联合重组人促血小板生成素治疗特发性血小板减少性紫癜[J].血栓与止血学,2014,20(2):79.